Brand-Name, Generics Deals Stifle Competition: FTC
"This report confirms that settlements with potentially anti-competitive arrangements continue to be prevalent," said FTC Chairman William E. Kovacic. "The commission remains committed to ensuring that brand and generic companies do not use such settlements as a way to deny consumers the benefits of competition."
There were 33 final settlements in pharmaceutical patent cases...
To view the full article, register now.